Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants

Abdelkader, Hamdy; Fathalla, Zeinab; Seyfoddin, Ali; Farahani, Mojtaba; Thrimawithana, Thilini; Allahham, Ayman; Alani, Adam W.G.; Al-Kinani, Ali A.; Alany, Raid G.

doi:10.1016/j.addr.2021.113957

Cited by 57 publications

(23 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shorter term implants such as Dextenza R , a PEGbased cylindrical implant, utilize the controlled release properties of PEG by slowing hydrolytic erosion to provide 1 month of dexamethasone release for both inflammation and pain management after surgery. The device is implanted through intracanalicular insertion, has been FDA approved since 2018 for its indicated use, and is currently in phase 3 clinical trials for treatment of allergic conjunctivits (23). Additional products from Ocular Therapeutix, such as their dexamethasone intracanalicular ophthalmic insert (OTX-DED) and tyrosine kinase inhibitor (OTX-TKI), use PEG.…”

Section: Polyethylene Oxidesmentioning

confidence: 99%

Considerations for Polymers Used in Ocular Drug Delivery

et al. 2022

View full text Add to dashboard Cite

PurposeAge-related eye diseases are becoming more prevalent. A notable increase has been seen in the most common causes including glaucoma, age-related macular degeneration (AMD), and cataract. Current clinical treatments vary from tissue replacement with polymers to topical eye drops and intravitreal injections. Research and development efforts have increased using polymers for sustained release to the eye to overcome treatment challenges, showing promise in improving drug release and delivery, patient experience, and treatment compliance. Polymers provide unique properties that allow for specific engineered devices to provide improved treatment options. Recent work has shown the utilization of synthetic and biopolymer derived biomaterials in various forms, with this review containing a focus on polymers Food and Drug Administration (FDA) approved for ocular use.MethodsThis provides an overview of some prevalent synthetic polymers and biopolymers used in ocular delivery and their benefits, brief discussion of the various types and synthesis methods used, and administration techniques. Polymers approved by the FDA for different applications in the eye are listed and compared to new polymers being explored in the literature. This article summarizes research findings using polymers for ocular drug delivery from various stages: laboratory, preclinical studies, clinical trials, and currently approved. This review also focuses on some of the challenges to bringing these new innovations to the clinic, including limited selection of approved polymers.ResultsPolymers help improve drug delivery by increasing solubility, controlling pharmacokinetics, and extending release. Several polymer classes including synthetic, biopolymer, and combinations were discussed along with the benefits and challenges of each class. The ways both polymer synthesis and processing techniques can influence drug release in the eye were discussed.ConclusionThe use of biomaterials, specifically polymers, is a well-studied field for drug delivery, and polymers have been used as implants in the eye for over 75 years. Promising new ocular drug delivery systems are emerging using polymers an innovative option for treating ocular diseases because of their tunable properties. This review touches on important considerations and challenges of using polymers for sustained ocular drug delivery with the goal translating research to the clinic.

show abstract

Section: Polyethylene Oxidesmentioning

confidence: 99%

Considerations for Polymers Used in Ocular Drug Delivery

et al. 2022

View full text Add to dashboard Cite

show abstract

“…With the advance of bionanotechnology, drug delivery scientists launched several innovative drug delivery systems to satisfy various clinical situations [ 5 ]: 1) the pulsatile drug delivery systems (PDDS) [ 6 ]; 2) dynamic nanoassembly-based drug delivery systems (DNDDS) [ 7 ]; and, 3) long-acting drug delivery systems (LADDS) [ 8 ].…”

Section: Evolution Of Drug Delivery Sciencementioning

confidence: 99%

“…Long-acting drug delivery systems (LADDS) provide a more extended period of therapeutic effects from a single dosage by optimizing the drug's pharmacokinetics and pharmacodynamic activity. The sustained drug-releasing duration ameliorates patient compliance with less frequent dosing, enhances comfort by eliminating repeated injections, and provides localized, site-specific drug delivery [ 8 ].…”

Section: Evolution Of Drug Delivery Sciencementioning

confidence: 99%

Potential next-generation medications for self-administered platforms

Chen

Cheng

2022

Journal of Controlled Release

View full text Add to dashboard Cite

“…( a ) Cross section of a human eye showing the inserting/injection positions of commercially available ocular IDDSs. Reproduced from [ 73 ], with permission from Elsevier. ( b ) Migration of Iluvien implant in the inferior angle of anterior chamber.…”

Section: Figurementioning

confidence: 99%

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

et al. 2021

View full text Add to dashboard Cite

Precise delivery of therapeutics to the target structures is essential for treatment efficiency and safety. Drug administration via conventional routes requires overcoming multiple transport barriers to achieve and maintain the local drug concentration and commonly results in unwanted off-target effects. Patients’ compliance with the treatment schedule remains another challenge. Implantable drug delivery systems (IDDSs) provide a way to solve these problems. IDDSs are bioengineering devices surgically placed inside the patient’s tissues to avoid first-pass metabolism and reduce the systemic toxicity of the drug by eluting the therapeutic payload in the vicinity of the target tissues. IDDSs present an impressive example of successful translation of the research and engineering findings to the patient’s bedside. It is envisaged that the IDDS technologies will grow exponentially in the coming years. However, to pave the way for this progress, it is essential to learn lessons from the past and present of IDDSs clinical applications. The efficiency and safety of the drug-eluting implants depend on the interactions between the device and the hosting tissues. In this review, we address this need and analyze the clinical landscape of the FDA-approved IDDSs applications in the context of the foreign body reaction, a key aspect of implant–tissue integration.

show abstract

Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants

Cited by 57 publications

References 218 publications

Considerations for Polymers Used in Ocular Drug Delivery

Considerations for Polymers Used in Ocular Drug Delivery

Potential next-generation medications for self-administered platforms

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

Contact Info

Product

Resources

About